Clinical Trial Update: Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating first-line checkpoint inhibitor combination therapy for hepatocellular carcinoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Checkpoint inhibitor combination therapy

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Liver Cancer, Antibody | Phase 2 | Status: RECRUITING